Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 10/20 | 0.40 |
| ▸ | CTSS | P25774 | 6/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963013 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL1128594 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL30965306 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL12676810 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL15083313 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL16289367 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL15987032 | 0.85 | L3MBTL1 (0.34) | SMN1; SMN2CTSKMAPTPOLBNPSR1 | |
| SCHEMBL14684362 | 0.84 | CTSK (0.56) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL14681218 | 0.84 | CTSK (0.43) | SMN1; SMN2CTSKCTSSCTSLCTSB | |
| SCHEMBL1818008 | 0.84 | CTSK (0.43) | SMN1; SMN2CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308282-B2 | [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9308282-B2 | [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation | PIRAMAL IMAGING SA (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-9238631-B2 | Radiolabeled amino acids for diagnostic imaging | PIRAMAL IMAGING SA (CH) | 2016-01-19 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | PIRAMAL IMAGING SA (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | LIFE MOLECULAR IMAGING SA (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | LIFE MOLECULAR IMAGING SA (CH) | 2014-06-05 | — | — | US | disclosed |
| WO-2011060887-A2 | METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061154-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
| EP-2322171-A2 | Fluorine labeled L-glutamic acid derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322171-A2 | Fluorine labeled L-glutamic acid derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2009141090-A9 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009141090-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011773-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | SLC1A5, SLC6A19, BCAT2 | SMN1; SMN2 2934/4885CTSK 627/4885CTSS 809/4885 |
| US-20100290991-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | GLUL, QPCT, SLC1A2 | SMN1; SMN2 2566/4885CTSK 2573/4885CTSS 2938/4885 |
| US-20140154183-A1 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION | GLUL, QPCT, SLC1A2 | SMN1; SMN2 2566/4885CTSK 2573/4885CTSS 2938/4885 |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | GLUL, GATD3, QPCT | SMN1; SMN2 3806/4885CTSK 2187/4885CTSS 2870/4885 |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | GLUL, GATD3, QPCT | SMN1; SMN2 3474/4885CTSK 2281/4885CTSS 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.